People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ivenix, Inc. | — | Biotechnology | Series B | $82.9M | $396.9M | 2009 |
Jeffrey Carlisle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Carlisle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ketan Patel | 1 | 10 |
| John Clarke | 1 | 8 |
| Wei Li | 1 | 7 |
| Wayne B. Weisman | 1 | 5 |
| John K. Clarke | 1 | 5 |
| Brandon Hull | 1 | 5 |
| John Wu | 1 | 4 |
| Ketan K. Patel | 1 | 2 |
| Charles Hadley | 1 | 2 |
| Colin J. Foster | 1 | 2 |
| Darrell Crate | 1 | 2 |
| John M. Douglass | 1 | 1 |
| John M. Sokolowski | 1 | 1 |
| Jesse M. Ambrosina | 1 | 1 |
| Darrell J. Crate | 1 | 1 |
| George W. Gray | 1 | 1 |
| Carolyn M. Malleck | 1 | 1 |
| Stuart Randle | 1 | 1 |
| Thomas Bassinger | 1 | 1 |
| Brent Nibarger | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.